PATENT CLAIM ANALYSIS

Application Number: 16382726
Application Type: Utility
Filing Date: 2019-04
Publication Date: 2019-10
Patent Classification: ["514", "049000"]

Abstract:
Methods for treating cancer by administration of two or more therapeutic agents are provided. The two or more therapeutic agents include a cyclin-dependent kinase inhibitor (e.g., alvocidib) and an anthracycline (e.g., daunorubicin or idarubicin). Kits comprising the two or more therapeutic agents that can be used to perform such methods are also provided.

Claim (Index 14):
The method of  claim 1 , wherein daunorubicin, or a pharmaceutically acceptable salt thereof, is administered to the subject intravenously.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 100.0
- Lexical Diversity: 1.44186
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12730097', '11811626', '12032583', '14315930', '14009021']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7507034380856576
- 35 USC 102 Novelty (BERT): 0.5271881916389513
- Combined Prediction Score: 0.728351913440987
- Mean Citation Score: 273.01801600000005
- Max Citation Score: 319.75333
- Similarity Product: 245.35323226461827

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test